Efficacy, Immunogenicity and Safety of adjuvanted Herpes Zoster-Virus Subunit Vaccine Candidates in Adults from 60 Years and older: Results from the Efficacy Studies ZOE-50 and ZOE-70
conference contribution
posted on 2018-04-01, 00:00authored byJanet McElhaney, Himal Lal, Anthony Cunningham, Myron Levin, Roman Chlibek, Javier Diez-Domingo, Eugene AthanEugene Athan, Johan Berglund, Jackson Downey, Wayne Ghesquiere, Olivier Godeaux, Iris Gorfinkel, Shinn-Jang Hwang, Tiina Korhonen, Shelly McNeil, Karlis Pauksens, Joan Puig-Barbera, Thiago Avelino-Silva, Timo Vesikari, Antonio Volpi, Daisuke Watanabe, Wilfried Yeo, Laura Campora, Carline Vanden Abeele, Lidia Oostvogels, Thomas Heinemann, Johannes Hain
Efficacy, Immunogenicity and Safety of adjuvanted Herpes Zoster-Virus Subunit Vaccine Candidates in Adults from 60 Years and older: Results from the Efficacy Studies ZOE-50 and ZOE-70